Development and validation of an analytical method for the simultaneous quantitation of posaconazole Form I and Form-S in oral suspensions
Journal of Pharmaceutical and Biomedical Analysis · 2025
DOI: 10.1016/j.jpba.2024.116569 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2025. Verfasst von Michail Lykouras und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Engineering Sciences, Foundation of Research and Technology-Hellas (ICE-HT/FORTH), Platani, Achaias GR-26504, Greece. Electroni…. Hauptthemen laut MEDLINE: Triazoles, Suspensions, Spectrum Analysis, Raman, Antifungal Agents. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Any polymorphic conversion of an active pharmaceutical ingredient (API), even if partial, is likely to lead to changes in its efficiency and safety. Posaconazole, an antifungal drug, is detected as Form-S in the commercially available oral suspensions. However, a mixture of Form-S and the initial Form I is likely to coexist depending either on the manufacturing process of the suspensions and/or to the storage conditions of the suspension. The simultaneous quantitation of these crystal forms in suspensions is challenging because of the dose inhomogeneity and the instability of Form-S at ambient conditions. Although X-ray Powder Diffraction (XRPD) was initially employed, preferred orientation issues in the suspension inhibited the successful quantitative determination of the polymorphs. In order to circumvent the problem Raman spectroscopy was selected for addressing this challenge, while the additional application of a home-made rotation system reduced the inhomogeneity problems. A separate calibration curve was generated for each polymorph using a conventional linear regression. The combination of these two relations led to the formation of a comprehensive equation relating the characteristic Raman peak intensities of posaconazole Form-S and Form I with the concentrations thereof. The method was validated and the results were confirmed through a partial least square regression (PLSR). The detection limits for Form-S and Form I were determined equal to 1.9 mg/mL and 2.2 mg/mL, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chemical Engineering Sciences, Foundation of Research and Technology-Hellas (ICE-HT/FORTH), Platani, Achaias GR-26504, Greece. Electronic address: lykouras@iceht.forth.gr.
- Institute of Chemical Engineering Sciences, Foundation of Research and Technology-Hellas (ICE-HT/FORTH), Platani, Achaias GR-26504, Greece; Department of Pharmacy, University of Patras, Rio, Achaias GR-26504, Greece. El…
- Department of Pharmacy, University of Patras, Rio, Achaias GR-26504, Greece. Electronic address: malbie@upatras.gr.
Zitieren
APA
Lykouras, M., Kontoyannis, C., & Orkoula, M. (2025). Development and validation of an analytical method for the simultaneous quantitation of posaconazole Form I and Form-S in oral suspensions. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2024.116569
Vancouver
Lykouras M, Kontoyannis C, Orkoula M. Development and validation of an analytical method for the simultaneous quantitation of posaconazole Form I and Form-S in oral suspensions. Journal of Pharmaceutical and Biomedical Analysis. 2025. doi:10.1016/j.jpba.2024.116569
BibTeX
@article{Lykouras2025,
author = {Lykouras, Michail and Kontoyannis, Christos and Orkoula, Malvina},
title = {Development and validation of an analytical method for the simultaneous quantitation of posaconazole Form I and Form-S in oral suspensions},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2025},
doi = {10.1016/j.jpba.2024.116569}
}
EUVIMED